Last10K.com

Pfizer Inc (PFE) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

PFE Annual Reports

  • 10-K Annual Report February 2022
  • 10-K Annual Report February 2021
    10-K Annual Report February 2020
    10-K Annual Report February 2019
    10-K Annual Report February 2018
    10-K Annual Report February 2017
    10-K Annual Report February 2016
    10-K Annual Report February 2015
    10-K Annual Report February 2014

Pfizer Inc

CIK: 78003 Ticker: PFE
Exhibit 99
pfizerlogoa.jpg
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS
Full-Year 2021 Revenues of $81.3 Billion, Reflecting 92% Operational Growth; Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 6% Operationally to $44.4 Billion
Fourth-Quarter 2021 Revenues of $23.8 Billion, Reflecting 106% Operational Growth; Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Declined 2% Operationally Driven Primarily by the Impact of Fewer Selling Days Compared to the Prior-Year Quarter
Full-Year 2021 Reported Diluted EPS(2) of $3.85, Adjusted Diluted EPS(3) of $4.42; Fourth-Quarter 2021 Reported Diluted EPS(2) of $0.59, Adjusted Diluted EPS(3) of $1.08
Provides Full-Year 2022 Record-High Guidance(4) for Revenues of $98.0 to $102.0 Billion and Adjusted Diluted EPS(3) of $6.35 to $6.55, Reflecting 23% and 46% Year-Over-Year Growth at the Midpoints, Respectively
Raises 2022 Revenue Guidance for Comirnaty(1) to Approximately $32 Billion, Reflecting Doses Expected to be Delivered Under Supply Contracts Signed as of Late-January
Issues Initial 2022 Revenue Guidance for Paxlovid of Approximately $22 Billion, Reflecting Treatment Courses Expected to be Delivered Primarily Under Supply Contracts Signed or Committed as of Late-January
Provides Updates and New Data for Select Clinical Programs Spanning Vaccines, Hospital, Oncology, Rare Disease and Internal Medicine on Analyst Conference Call
NEW YORK, NY, Tuesday, February 8, 2022 – Pfizer Inc. (NYSE: PFE) reported strong financial results for fourth-quarter and full-year 2021 and provided 2022 total company financial guidance
(4). In addition, Pfizer raised its previous 2022 revenue guidance for Comirnaty(1), the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, and provided for the first time 2022 revenue guidance for its oral COVID-19 treatment, Paxlovid.
The fourth-quarter 2021 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found on the Pfizer website.
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “In the early days of the COVID-19 pandemic, we committed to use all of the resources and expertise we had at our disposal to help protect populations globally against this deadly virus, as well as to offer treatments to help avoid the worst outcomes when infections do occur. We put billions of dollars of capital on the line in pursuit of those goals, not knowing whether those investments would ever pay off. Now, less than two years since we made that commitment, we are proud to say that we have delivered both the first FDA-authorized vaccine against COVID-19 (with our partner, BioNTech) and the first FDA-authorized oral treatment for COVID-19.”
- 1 -

The following information was filed by Pfizer Inc (PFE) on Tuesday, February 8, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Pfizer Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pfizer Inc.

Continue

Assess how Pfizer Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Pfizer Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Legal
Revenue
M & A
Other
Filter by Subcategory:
All
Earnings
Expense
Income
Product
Shares
Cash Flow
Geography
Dividend
Debt
Other
Inside Pfizer Inc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Cash Flows (Parenthetical)
Consolidated Statements Of Comprehensive Income
Consolidated Statements Of Equity
Consolidated Statements Of Equity (Parenthetical)
Consolidated Statements Of Income
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)
Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements And Collaborative Arrangements
Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements And Collaborative Arrangements (Tables)
Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements And Collaborative Arrangements - Acquisitions (Details)
Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements And Collaborative Arrangements - Collaborative Arrangements (Detail)
Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements And Collaborative Arrangements - Divestitures (Details)
Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements And Collaborative Arrangements - Equity Method Investment (Details)
Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements And Collaborative Arrangements - Licensing Arrangements (Details)
Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements And Collaborative Arrangements - Schedule Of Collaborative Arrangements And Non-Collaborative Arrangement Transactions (Details)
Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements And Collaborative Arrangements - Summarized Financial Information Of Discontinued Operations (Details)
Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements And Collaborative Arrangements - Summarized Financial Information Of Equity Method Investee (Details)
Basis Of Presentation And Significant Accounting Policies
Basis Of Presentation And Significant Accounting Policies (Policies)
Basis Of Presentation And Significant Accounting Policies (Tables)
Basis Of Presentation And Significant Accounting Policies - Accrued Rebates And Other Accruals (Details)
Basis Of Presentation And Significant Accounting Policies - Narrative (Details)
Basis Of Presentation And Significant Accounting Policies - Summary Of Change In Accounting Principle (Details)
Contingencies And Certain Commitments
Contingencies And Certain Commitments (Certain Commitments And Contingent Consideration For Acquisitions) (Details)
Contingencies And Certain Commitments (Patent Litigation) (Details)
Contingencies And Certain Commitments (Product Litigation, Commercial And Other Matters, Resolved Matters) (Details)
Earnings Per Common Share Attributable To Pfizer Inc. Common Shareholders
Earnings Per Common Share Attributable To Pfizer Inc. Common Shareholders (Details)
Earnings Per Common Share Attributable To Pfizer Inc. Common Shareholders (Tables)
Equity
Equity (Tables)
Equity - Narrative (Details)
Equity - Summary Of Common Stock Purchases (Details)
Financial Instruments
Financial Instruments (Tables)
Financial Instruments - Assets And Liabilities Not Measured At Fair Value On A Recurring Basis (Details)
Financial Instruments - Credit Risk (Details)
Financial Instruments - Cumulative Basis Adjustments For Fair Value Hedges (Details)
Financial Instruments - Derivative Financial Instruments And Hedging Activities (Details)
Financial Instruments - Derivative Financial Instruments And Hedging Activities - Footnotes (Details)
Financial Instruments - Derivative Financial Instruments And Hedging Activities- Narrative (Details)
Financial Instruments - Fair Value Of Derivative Financial Instruments And Related Notional Amounts (Details)
Financial Instruments - Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis (Details)
Financial Instruments - Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis - Footnotes (Details)
Financial Instruments - Investments - Debt Securities (Details)
Financial Instruments - Investments - Short-Term, Long-Term And Equity Method Investments (Details)
Financial Instruments - Investments - Unrealized Gains And Losses Related To Equity Securities (Details)
Financial Instruments - Investments - Unrealized Gains And Losses Related To Equity Securities - Footnotes (Details)
Financial Instruments - Long-Term Debt (Details)
Financial Instruments - Long-Term Debt, Narrative (Details)
Financial Instruments - Long-Term Debt, New Issuances (Details)
Financial Instruments - Short-Term Borrowings (Details)
Identifiable Intangible Assets And Goodwill
Identifiable Intangible Assets And Goodwill (Tables)
Identifiable Intangible Assets And Goodwill - Expected Annual Amortization Expense (Details)
Identifiable Intangible Assets And Goodwill - Finite-Lived And Indefinite-Lived Intangible Assets (Details)
Identifiable Intangible Assets And Goodwill - Goodwill (Details)
Identifiable Intangible Assets And Goodwill - Narrative (Details)
Leases
Leases (Tables)
Leases - Narrative (Details)
Leases - Schedule Of Future Minimum Rental Payments For Operating Leases (Detail)
Leases - Schedule Of Lease Assets And Liabilities (Details)
Leases - Schedule Of Lease Costs And Other Supplemental Information (Details)
Other (Income)/Deductions - Net
Other (Income)/Deductions - Net (Tables)
Other (Income)/Deductions - Net - Schedule Of Other Nonoperating Income (Expense) (Details)
Other (Income)/Deductions - Net - Schedule Of Other Nonoperating Income (Expense) - Footnotes (Details)
Other Financial Information
Other Financial Information (Tables)
Other Financial Information - Inventories (Details)
Other Financial Information - Other Current Liabilities (Details)
Pension And Postretirement Benefit Plans And Defined Contribution Plans
Pension And Postretirement Benefit Plans And Defined Contribution Plans (Tables)
Pension And Postretirement Benefit Plans And Defined Contribution Plans - Analysis Of Changes In Significant Investments Valued Using Significant Unobservable Inputs (Details)
Pension And Postretirement Benefit Plans And Defined Contribution Plans - Expected Future Cash Flow Information (Details)
Pension And Postretirement Benefit Plans And Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)
Pension And Postretirement Benefit Plans And Defined Contribution Plans - Narrative (Details)
Pension And Postretirement Benefit Plans And Defined Contribution Plans - Obligations And Funded Status (Details)
Pension And Postretirement Benefit Plans And Defined Contribution Plans - Plan Assets (Details)
Pension And Postretirement Benefit Plans And Defined Contribution Plans - Schedule Of Net Periodic Benefit Costs (Details)
Pension And Postretirement Benefit Plans And Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)
Property, Plant And Equipment (Pp&Amp;E)
Property, Plant And Equipment (Pp&Amp;E) (Tables)
Property, Plant And Equipment (Pp&Amp;E) - Components Of Property, Plant And Equipment (Details)
Property, Plant, And Equipment (Pp&Amp;E) - Long-Lived Assets By Geographic Areas (Details)
Restructuring Charges And Other Costs Associated With Acquisitions And Cost-Reduction/Productivity Initiatives
Restructuring Charges And Other Costs Associated With Acquisitions And Cost-Reduction/Productivity Initiatives (Tables)
Restructuring Charges And Other Costs Associated With Acquisitions And Cost-Reduction/Productivity Initiatives - Costs (Detail)
Restructuring Charges And Other Costs Associated With Acquisitions And Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)
Restructuring Charges And Other Costs Associated With Acquisitions And Cost-Reduction/Productivity Initiatives - Narrative (Detail)
Restructuring Charges And Other Costs Associated With Acquisitions And Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)
Restructuring Charges And Other Costs Associated With Acquisitions And Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)
Segment, Geographic And Other Revenue Information
Segment, Geographic And Other Revenue Information (Tables)
Segment, Geographic And Other Revenue Information - Narrative (Detail)
Segment, Geographic And Other Revenue Information - Revenues By Geographic Area (Detail)
Segment, Geographic And Other Revenue Information - Revenues By Products (Detail)
Segment, Geographic And Other Revenue Information - Schedule Of Segment Reporting Information By Segment (Details)
Segment, Geographic And Other Revenue Information - Schedules Of Concentration Of Risk (Details)
Share-Based Payments
Share-Based Payments (Tables)
Share-Based Payments - Narrative (Detail)
Share-Based Payments - Schedule Of Share-Based Compensation Awards And Valuation Details (Details)
Share-Based Payments - Schedule Of Share-Based Compensation, Stock Options, Activity (Detail)
Share-Based Payments - Schedule Of Share-Based Payment Arrangement Activity (Detail)
Share-Based Payments - Schedule Of Valuation Assumptions (Detail)
Share-Based Payments - Summary Of Data Related To Share-Based Payment Arrangement Activity (Details)
Share-Based Payments - Summary Of Tsru And Ptu Information (Details)
Tax Matters
Tax Matters (Tables)
Tax Matters - Deferred Taxes (Details)
Tax Matters - Deferred Taxes - Footnotes (Details)
Tax Matters - Income From Continuing Operations Before Provision For Taxes On Income (Details)
Tax Matters - Narrative (Details)
Tax Matters - Provision For Taxes On Income (Details)
Tax Matters - Reconciliation Of Gross Unrecognized Tax Benefits (Details)
Tax Matters - Reconciliation Of Gross Unrecognized Tax Benefits - Footnotes (Details)
Tax Matters - Tax Rate Reconciliation (Details)
Tax Matters - Taxes On Items Of Other Comprehensive Income/(Loss) (Details)
Ticker: PFE
CIK: 78003
Form Type: 10-K Annual Report
Accession Number: 0000078003-22-000027
Submitted to the SEC: Thu Feb 24 2022 2:25:01 PM EST
Accepted by the SEC: Thu Feb 24 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/pfe/0000078003-22-000027.htm